Skip to main content

Table 1 Endomyocardial biopsy scores of patients treated with high cumulative doses of pegylated liposomal doxorubicin

From: Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review

Patient Age Sex Underlying disease Prior doxorubicin dose (mg/m2) Cumulative PLD dose (mg/m2) Billingham score Reference
1 Unknown M KS 0 500 1 [25]
2 Unknown M KS 0 541 0 [25]
3 35 F Breast cancera 180 564 0.5 [26]
4 Unknown M KS 0 578 0 [25]
5 Unknown M KS 0 610 0.5 [25]
6 54 F Breast cancera 0 675 0.5 [27]
7 47 F Breast cancera 0 685 0 [26]
8 66 F Ovarian cancer 0 730 0 [26]
9 Unknown M KS 0 780 0 [25]
10 Unknown M KS 0 801 0.5 [25]
11 Unknown M KS 0 860 0 [25]
12 36 F Ovarian cancer 375 952 0 [26]
13 52 F Breast cancera 360 1320 1.5 [26]
14 49 F Breast cancer 0 1485 1 [26]
  1. Abbreviations: M Male, F Female, KS Kaposi sarcoma, PLD Pegylated liposomal doxorubicin
  2. aPatients 3, 6, 7, and 13 received prior radiotherapy to the breast